CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.

CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Feb; 9(2):214-21.

View in: PubMed

subject areas

Adenocarcinoma
Aged
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Female
Follow-Up Studies
Glutamates
Guanine
Humans
Indoles
Lung Neoplasms
Male
Middle Aged
Neoplasm Staging
Pemetrexed
Prognosis
Pyrroles
Remission Induction
Salvage Therapy
Survival Rate

authors with profiles

Everett E. Vokes